Navigation Links
Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
Date:3/31/2008

>

ONTARGET also studied the value of combining telmisartan with ramipril, to evaluate whether combining an ACE inhibitor and an ARB, i.e. the dual renin-angiotensin system (RAS) blockade, could offer even better risk reduction compared to single blockade, a key question for the clinical community. The results announced today indicate that there was no additional risk reduction benefit achieved and a higher discontinuation rate if telmisartan and ramipril are combined.(1)

About the ONTARGET(TM) Trial Program

The ONTARGET Trial Program is the largest clinical trial ever undertaken with an ARB, involving more than 31,000 high-risk cardiovascular patients with either normal or controlled blood pressure. The ONTARGET Trial Program encompasses two randomized, double-blind, multi-center international outcome trials: ONTARGET, the main trial with results reported today, and TRANSCEND(TM) (Telmisartan Randomized Assessment Study in ACE-intolerant subjects with cardiovascular disease), the parallel trial with results planned to be reported later in 2008.

ONTARGET evaluated more than 25,600 high-risk cardiovascular patients with normal blood pressure or controlled high blood pressure and a history of a broad range of cardiovascular diseases. The study compared the effectiveness of the ARB telmisartan to the ACE inhibitor ramipril in reducing the combined risk of cardiovascular death, myocardial infarction, stroke and hospitalization for congestive heart failure (CHF) in patients at risk. The study also compared the efficacy of the combination of the ARB telmisartan and the ACE inhibitor ramipril compared to ramipril alone in achieving the same combined endpoint.

The combined primary endpoint in the ONTARGET trial included cardiovascular death, non-fatal myocardial infarction, non-fatal stroke and hospitalization for congestive heart failure. In addition, a broad variety of secondary and tertiary endpoints were studied, including: newly diagnosed d
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
2. Viatronix V3D-Colon Utilized in Another Landmark Study
3. Long-Term Data from a Landmark Phase III Trial Show Survival Benefit at Three- and Four-Years in Patients with Glioblastoma multiforme
4. Hospital Launches Landmark Emergency Medicine Project
5. JACC Identifies DEFER with 5-year Outcomes as Landmark Trial
6. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... --  Mary,s Medicinals today announced that its 501(c)(3) ... of Operation Grow4Vets , a national, nonpartisan organization ... services to assist them in living with injuries sustained ... , An ever-increasing number of medical studies have ... for pain, Post-traumatic Stress Disorder (PTSD) and Traumatic Brain ...
(Date:10/19/2014)... , October 20, 2014 Shire plc ... Bowling , Interim Chief Financial Officer (CFO), has notified the Board ... role to pursue a new career opportunity as CFO of Severn ... 2015 and the company will commence a search for a new ... "James has helped build and lead a high-quality finance ...
(Date:10/19/2014)... Deutschland, October 19, 2014 ... Das Problem dabei ist, dass große ... der Kompetenz zu teilen. Es war ... freuen wir uns umso mehr, dass es uns ... Gepflogenheiten bei Kühlketten aufzuschreiben - mit einem Vorbehalt ...
Breaking Medicine Technology:Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 2Mary's Medicinals Announces 4-Star Sponsorship of Operation Grow4Vets 3Interim Chief Financial Officer James Bowling to Step Down 2Interim Chief Financial Officer James Bowling to Step Down 3Interim Chief Financial Officer James Bowling to Step Down 4Vergleichsbericht zu Pharma-Kühlketten und CRT 2
... an international generic pharmaceuticals company, today announced that ... Food & Drug Administration to market Zolpidem Tartrate ... the product has commenced.   Actavis ... Extended-Release Tablets 6.25 mg strength in October 2010 with ...
... 6, 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ... the Phase IB/II study of the Btk inhibitor, PCI-32765, ... (CLL/SLL) at the 2011 American Society of Clinical Oncology ... development program update for the Btk Inhibitor, PCI-32765.  The ...
Cached Medicine Technology:Actavis Receives FDA Approval of Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV in the U.S. 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 7Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 8Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765 9
(Date:10/20/2014)... Rockynol Retirement Community broke ... 14. The $11 million project will include the latest ... kitchen with full-service restaurant style dining. , “We are ... class Assisted Living apartments,” said Kara Hanzie, Rockynol Executive ... quality of care and this investment is proof of ...
(Date:10/20/2014)... 20, 2014 Based on a ... only imaging assays capable of determining DNA sequence, ... With these three dimensions of high-resolution data, dGH ... the widest range of disease-causing genetic rearrangements, including ... other genomic tools, including today’s advanced sequencing technologies. ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Final Cut Pro ... release of the Citrus theme for FCPX filmmakers . ... use to describe the Citrus theme” Says Christina Austin, CEO ... to look so professional.” , Citrus comes with all the ... the template are: four transitions for added style, a title ...
(Date:10/20/2014)... hard to imagine what it’s like to live without shoes, ... it’s a reality. And while new shoes are considered a ... barefoot on rocky terrain or sewage-lined streets just to collect ... , Buckner International's Shoes for Orphan Souls project ... encourage support for Air1 and while also providing new shoes ...
(Date:10/20/2014)... October 20, 2014 Houston plastic surgeon ... the key elements of his innovative True Form ... plastic surgery residents and faculty at The University ... he, too, was once a medical student. Patronella, who ... private cosmetic plastic surgery practices in Texas, The ...
Breaking Medicine News(10 mins):Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... Pediatricians look to help those at risk of obesity ... News) -- For babies ready to graduate from breast ... has been that they receive whole milk, instead of ... the American Academy of Pediatrics (AAP) now advise parents ...
... China Medicine,Corporation (OTC Bulletin Board: CHME; "China ... developer of ethical and over-the-counter drugs,traditional Chinese ... and medical formulations in the People,s Republic ... a patent from Australia Patent,Office for recombinant ...
... Harvest Products,Inc. (OTC Bulletin Board: FRHV.OB) announced today ... commitment to providing consumers with the,best, natural and ... natural and organic brands and products, including non-food,environmentally-friendly ... network., "We believe that this new initiative ...
... July 17 /Xinhua-PRNewswire-FirstCall/ -- Mindray,Medical International Limited (NYSE: ... of medical devices worldwide has announced today that ... products as well as,unveil three new units and ... Chemistry (AACC) conference. The conference will be attended,by ...
... CITY, Calif., July 17 Cardica, Inc.,(Nasdaq: ... Bauer to the,position of vice president, operations. Mr. ... international operations and manufacturing experience to,Cardica from large ... extensive operations experience and his continuous drive to,improve ...
... Date of January 2, 2009 -, LAVAL, QC, ... today announced that the response that it submitted to ... 2008, including the,additional analysis of existing data as suggested ... 2 response. The action date assigned by the,FDA under ...
Cached Medicine News:Health News:Low-Fat Milk OK for Some Toddlers 2Health News:China Medicine Corporation Obtains Australian Patent for rADTZ 2Health News:China Medicine Corporation Obtains Australian Patent for rADTZ 3Health News:Fresh Harvest Products, Inc. Announces New Brand Initiative 2Health News:Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 2Health News:Mindray to Unveil Three New Products and Reagents at AACC Annual Meeting 3Health News:Cardica Names Frederick Bauer Vice President of Operations 2Health News:Cardica Names Frederick Bauer Vice President of Operations 3Health News:FDA accepts Labopharm's response for once-daily tramadol as complete Class 2 response 2
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
The Soft-Touch Timeter® Flowmeter is durable, long-lasting and easy to maintain. Timeter ® by Allied Flowmeters: Quality Plus Value....
... Amvex offers a complete line of ... and CO 2 . They are ... calibrations to best suit your application. ... specific to the gas in use, ...
... a complete line of flowmeters, available in oxygen, air, ... in a variety of calibrations to best suit your ... the gas in use, the Amvex Flowmeter is a ... U with I. For Power Take-Off add PT to ...
Medicine Products: